ANI Pharmaceuticals offers an attractively valued specialty pharmaceutical franchise trading at 7.7x forward earnings with a PEG of 0.09, free cash flow exceeding net income by 52%, and four consecutive earnings beats averaging a 29% positive surprise — yet near-term positioning is constrained by an 18% short interest, a failed critical filing gate, and single-source supplier concentration across key product lines.
Thesis pillars
- Consistent Earnings Outperformance↓Deteriorating
- Attractive Valuation Growth Premium→Stable
- Superior Cash Conversion Quality→Stable
- +1 more pillar — see the Why tab for full reasoning
ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $80.43, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source API per product; Concentration risk — Supplier: Cortrophin Gel and ILUVIEN contract manufacturers.
ANI Pharmaceuticals develops, manufactures, and commercializes pharmaceuticals through Rare Disease (Cortrophin Gel, ILUVIEN, YUTIQ), Generics (120+ products), and Brands (12 branded NDAs) segments from three facilities in Minnesota and New Jersey. The company acquired Alimera... Read more
Hold if already holding. Not a fresh buy at $80.43, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source API per product; Concentration risk — Supplier: Cortrophin Gel and ILUVIEN contract manufacturers. Chart setup: Death cross but MACD improving, RSI 45. Maintain position. Not compelling to add more. Score 6.9/10, moderate confidence.
Passes 5/10 gates (positive momentum, favorable risk/reward ratio, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on clean insider activity and death cross (50MA < 200MA) and SEC filing concern and earnings proximity 7d<=7d. Suitability: aggressive.
About ANI Pharmaceuticals, Inc.
About ANI Pharmaceuticals, Inc.
Cortrophin Gel, an ACTH therapy with FDA approvals for autoimmune indications including MS, RA, and nephrotic syndrome, generated a significant portion of ANI Pharmaceuticals' net product revenues in 2025. The company expanded its Rare Disease portfolio in September 2024 with the acquisition of Alimera Sciences, adding ILUVIEN — which received an expanded FDA label for NIU-PS in March 2025 in addition to its existing DME indication — and YUTIQ. Three manufacturing facilities in Baudette, Minnesota and East Windsor, New Jersey support oral solid dose, semi-solid, and potent product manufacturing.
ANI Pharmaceuticals earns revenue through three channels: Rare Disease branded products distributed via specialty pharmacy networks, branded legacy drugs sold through wholesale channels, and generics sold to pharmacy chains, wholesalers, and hospitals. Cortrophin Gel's specialty pharmacy distribution network was expanded in the second quarter of 2025 with a prefilled syringe format approved by FDA in February 2025. Cortrophin Gel and ILUVIEN cannot be manufactured in ANI's own facilities; both depend exclusively on third-party contract manufacturers. API for each product is generally qualified from a single source, with supplier changes requiring an FDA Prior Approval Supplement that can take six to nine months, and up to 19 months if additional data are needed. The Generics and Other segment holds 120+ products with an expected 10 to 15 new launches annually, while the Brands portfolio includes twelve branded NDAs including Atacand, Vancocin, and Inderal LA.
Show full overview
Manufacturing dependency is structural for the two highest-revenue products: Cortrophin Gel and ILUVIEN are produced exclusively by third-party contract manufacturers under arrangements ANI cannot directly control, and the API for each product qualifies from a single source. Any change to an API supplier requires an FDA Prior Approval Supplement taking six to nineteen months, creating a long replacement timeline if a sole-source supplier fails. The 10-K identifies Cortrophin Gel and ILUVIEN supply disruptions as potential material adverse effects, and notes that if a contract manufacturer fails to meet regulatory requirements, the company may be unable to commercialize these products with no rapid substitute readily available.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From ANI Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-30Recent Developments — ANI Pharmaceuticals, Inc.
Latest news
- NEWS Zacks.com featured highlights include Mirion Technologies, Intuit and ANI Pharmaceuticals - Yahoo Finance — Yahoo Finance neutral
- NEWS ANIP|ANI Pharmaceuticals Inc|Price:76.500|Chg%:-2.030 - TradingKey — TradingKey negative
- NEWS ANI Pharmaceuticals (ANIP) is a top-ranked momentum stock: Should you buy? - MSN — MSN positive
- NEWS Price to sales forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP - TradingView — TradingView neutral
- NEWS ANI Pharmaceuticals (ANIP) is a top-ranked growth stock: Should you buy? - MSN — MSN positive
Generated 2026-07-31T00:08:41Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductCortrophin Gel10-K Item 1A: 'a significant portion of our net product revenues were derived from the sale of Cotrophin Gel...sales of Cortrophin Gel will continue to account for a significant portion of our net product revenues'
- HIGHSuppliersingle-source API per product10-K Item 1A: 'we qualify only a single source of API for use in each product due to the cost and time required to validate and qualify a second source of supply'
- HIGHSupplierCortrophin Gel and ILUVIEN contract manufacturers10-K Item 1: 'We do not have in-house manufacturing capabilities for the production of Cortrophin Gel or ILUVIEN, and thus we depend, and expect to continue to depend, exclusively on third-party contract manufacturers'
Material Events(8-K, last 90d)
- 2026-04-07Item 4.01HIGHANI Pharmaceuticals dismissed EisnerAmper LLP as independent registered public accounting firm, effective April 1, 2026. Audit Committee approved the dismissal. No disagreements on accounting principles or practices cited. No successor named.SEC filing →
- 2026-05-21Item 5.02LOWStockholders approved Amended and Restated 2022 Stock Incentive Plan at ANI Pharmaceuticals' 2026 Annual Meeting on May 21, 2026. Routine compensatory arrangement approval; no officer departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $80.43, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source API per product; Concentration risk — Supplier: Cortrophin Gel and ILUVIEN contract manufacturers. Chart setup: Death cross but MACD improving, RSI 45. Maintain position. Not compelling to add more. Target $95.70 (+19.0%), stop $75.75 (−6.2%), A.R:R 3.3:1. Score 6.9/10, moderate confidence.
Take-profit target: $95.70 (+19.0% upside). Target $95.70 (+19.0%), stop $75.75 (−6.2%), A.R:R 3.3:1. Stop-loss: $75.75.
Concentration risk — Supplier: single-source API per product; Concentration risk — Supplier: Cortrophin Gel and ILUVIEN contract manufacturers; Leverage penalty (D/E 1.1): -0.5.
ANI Pharmaceuticals, Inc. trades at a P/E of 20.9 (forward 7.6). TrendMatrix value score: 8.2/10. Verdict: Hold.
13 analysts cover ANIP with a consensus score of 4.3/5. Average price target: $110.
What does ANI Pharmaceuticals, Inc. do?ANI Pharmaceuticals develops, manufactures, and commercializes pharmaceuticals through Rare Disease (Cortrophin Gel,...
ANI Pharmaceuticals develops, manufactures, and commercializes pharmaceuticals through Rare Disease (Cortrophin Gel, ILUVIEN, YUTIQ), Generics (120+ products), and Brands (12 branded NDAs) segments from three facilities in Minnesota and New Jersey. The company acquired Alimera Sciences in September 2024, adding an ophthalmic retinal franchise and international commercial operations in Germany, UK, Portugal, and Ireland. A significant portion of net product revenues is derived from Cortrophin Gel.